Images List Premium Download Classic

C Syndrome

C Syndrome-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Peptides having reduced toxicity that stimulate cholesterol efflux
The Regents Of The University Of California
October 05, 2017 - N°20170283480

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e. G., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also ...
Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 28, 2017 - N°20170275378

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
Antibodies that bind il-23
Eli Lilly And Company
September 28, 2017 - N°20170275356

The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host ...
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, ...
Mega Sun Biomedical Corp.
September 21, 2017 - N°20170267563

A negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth ...
Compositions and methods for diagnosis and treatment of metabolic syndrome
United States Of America, As Represented By The Secretary Of The Navy
September 21, 2017 - N°20170266144

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
Shionogi & Co., Ltd.
September 14, 2017 - N°20170260290

Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof
Fudan University
September 07, 2017 - N°20170253564

2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts are disclosed. The compounds can act as sphingomyelin synthase (sms) inhibitors to treat diseases caused by abnormal increasing of sphingomyelin (sm). The pharmaceutically acceptable salts and pharmaceutical compositions of the compounds are used as active ingredients in drugs which can prevent and cure diseases caused by sm level abnormal increase. These ...
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Famciclovir and celecoxib combination therapy for functional somatic syndromes
Innovative Med Concepts, Llc
August 31, 2017 - N°20170246134

The present invention relates to methods of treating fibromyalgia, by administering a therapeutically-effective combination of an antiviral component and a cox-2 inhibitor component. The invention is further related to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the cox-2 inhibitor celecoxib. The invention is also related to methods of ...
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
Boehringer Ingelheim Vetmedica Gmbh
August 24, 2017 - N°20170239281

The present invention relates to combination of one or more sglt2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more ...
Chemical compounds and use thereof for improving muscular quality
Universite Paris 6 Pierre Et Marie Curie
August 10, 2017 - N°20170226151

Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical ...
N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Universiteit Leiden
August 10, 2017 - N°20170226058

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency ...
Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes
Illinois Institute Of Technology
August 03, 2017 - N°20170216409

The disclosure provides methods of preventing or treating metabolic syndrome in a subject by administering an effective amount of an inhibitor of laminin α4 expression, laminin α4 activity, or both.
C Syndrome Patent Pack
Download + patent application PDFs
C Syndrome Patent Applications
Download + C Syndrome-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of C Syndrome-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Roasted laurina coffee, method for its preparation, and use for preventing metabolic syndrome
Illycaffe' S.p.a.
August 03, 2017 - N°20170216387

A roasted coffee of coffea arabica var. Laurina a powder of which comprises from 5. 0 to 10. 0 mg per gram of powder (mg/g) trigonelline and from 3. 0 to 8. 0 mg/g mono-caffeoylquinic acids (3-caffeoylquinic acid, 4-caffeoylquinic acid and 5-caffeoylquinic acid), the invention also relating to a beverage prepared with such roasted coffee, a method for the preparation and a use of such roasted ...
Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
Illycaffe' S.p.a.
July 27, 2017 - N°20170209539

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, ...
Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
H. Lee Moffitt Cancer Center And Research Institute, Inc.
July 27, 2017 - N°20170209434

Disclosed are methods for treating a meylodysplastic syndrome (mds) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2a (pp2a) inhibitor.
Preparation and use of crystalline beta-d-nicotinamide riboside
Glaxosmithkline Intellectual Property (no.2) Limited
July 20, 2017 - N°20170204131

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-d-nicotinamide riboside chloride compositions may be used to treat a disease or disorder that would benefit from increased nad levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, ...
Cobalt porphyrins for the treatment of blood-related disorders
Uniwersytet Jagiellonski
July 13, 2017 - N°20170196882

The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem ...
Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
Thymon, Llc
July 06, 2017 - N°20170190768

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the tnf monomer-specific epitope having the sequence psdkpvah ...
Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity ...
Consejo Superior De Investigaciones Cientificas
July 06, 2017 - N°20170189456

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of bacteroides uniforms, preferably cect 7771, or of the ...
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
Boehringer Ingelheim International Gmbh
July 06, 2017 - N°20170189437

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, ...
Loading